LungCast 2-longitudinal data
Research type
Research Study
Full title
A study into longer-term outcomes from the LUNGCAST study: comparing survival and healthcare utilisation according to smoking status in people with lung cancer, beyond 2 years.
IRAS ID
339817
Contact name
Keir Lewis
Contact email
Sponsor organisation
Hywel Dda University Health Board, Wales, UK.
Duration of Study in the UK
0 years, 3 months, 29 days
Research summary
Our 2010-2022 observational study 'LungCast' (Clinical Trials Identifier NCT01192256) followed over 3700 people newly diagnosed with lung cancer for at least 2 years, from 28 hospitals in England and Wales. We looked at any effects smoking may have on outcomes after controlling for other things such as age and type/spread of lung cancer. All patients received standard treatments. We have found crucial things:
1. More people who never smoked were alive at 2 years than both ex- and current smokers.
2. Smoking independently predicted of survival after accounting for age, spread of lung cancer and type of treatment
3. Stopping smoking was associated with significantly improved survival 17% (similar effect to having chemotherapy)
4. Smoking cessation treatments were likely to be cost-effective for people with lung cancer.
These results have been presented at international conferences and in 3 peer-reviewed journals.
LungCast was closed in 2022, but following discussions with newly appointed value-based researchers, and after seeking advice from the original LREC (Wales 7), our hospital sponsor and Health & Care Research Wales- we are seeking permission to re-access the original data set, and use their personally identifiable data (hospital number) to look in more detail at the approx 450 people who were diagnosed within our Health Board (Trust). We would like to see if smoking status also predicts longer term outcomes (5 years+) including survival and hospital appointments and admissions and if continued smoking is associated with more rapid cancer progression.
Finding survival advantage at 2 years has made us wonder if there are even longer-term survival advantages. We feel this can help answer other clinically important questions that are MORE meaningful to patients and help design and secure longer-term funding for specialist smoking cessation support for cancer services.REC name
London - City & East Research Ethics Committee
REC reference
24/LO/0429
Date of REC Opinion
31 May 2024
REC opinion
Favourable Opinion